Palisade Bio Reports Year End 2022 Financial Results and Provides Corporate Update
Phase 2 topline data readout for prevention of post-surgical abdominal adhesions on track for Q2 2023 Strong balance sheet with sufficient cash expected to fund operations into mid-2024 Carlsbad, CA, March 23, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade” or the “Company”), a biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, […]
Palisade Bio Receives Intention to Grant from European Patent Office for LB1148 Patent
Carlsbad, CA, March 01, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that European Patent Office (EPO) has issued a notice of intention to grant for its patent application titled, “Administration of Serine Protease Inhibitors to the Stomach.” […]
Palisade Bio Promotes Robert McRae to Chief Operating Officer
Mr. McRae is an industry veteran with a proven track record of operational, clinical, and strategic business development execution Carlsbad, CA, Feb. 08, 2023 — Palisade Bio, Inc. (Nasdaq: PALI) (the “Company”), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the promotion of Robert McRae to Chief […]
Palisade Bio Further Strengthens Balance Sheet with Early Exercise of Warrants Resulting in Cash Proceeds of $4.9 Million
Proceeds expected to extend cash runway to fund operations into the second half of 2024 Carlsbad, CA, Jan. 10, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications (the “Company”), today announced that holders of an additional 1.46 million common stock purchase […]
Palisade Bio to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Tuesday, January 17th at 3:00 PM ET Carlsbad, CA, Jan. 09, 2023 — Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that J.D. Finley, Interim Chief Executive Officer of Palisade Bio will present at the Virtual Investor 2023 Companies […]
Palisade Bio Announces Closing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, Jan. 04, 2023 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has closed its previously announced registered direct offering and concurrent private placement with institutional investors for the purchase of 1,052,631 shares of common stock (or […]
Palisade Bio Announces $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced Above Market Under Nasdaq Rules
Carlsbad, CA, Dec. 30, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is announcing today that it has entered into definitive agreements with institutional investors for the purchase of 1,052,631 shares of common stock (or certain pre-funded warrants in lieu thereof) in […]
Palisade Bio Provides Update on U.S. Phase 2 Study Evaluating LB1148 for Post-Surgical Abdominal Adhesions
Topline data readout from study expected in first half of 2023 Carlsbad, CA, Dec. 16, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, is providing an update on its U.S. Phase 2 study evaluating LB1148 for reduction in intra-abdominal adhesions in subjects […]
Palisade Bio Announces Early Exercise of Warrants Resulting in Cash Proceeds of $1.25 Million
Proceeds extend cash runway to fund operations into early 2024 Carlsbad, CA, Dec. 07, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that holders of 445,000 common stock purchase warrants (the “Warrants”), issued pursuant to the Company’s August 2022 public […]
Palisade Bio Regains Compliance with Nasdaq Listing Requirements
Carlsbad, CA, Dec. 01, 2022 — Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that on December 1, 2022, it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the Nasdaq Listing Rules for continued listing […]